Servier Gets FDA Approval for First Targeted Therapy for Grade 2 IDH-Mutant Glioma

By /

Servier Pharmaceuticals’ vorasidenib on Tuesday secured the FDA’s green light for the treatment of patients with grade 2 gliomas carrying mutations in the IDH gene.

Scroll to Top